Epilepsy affects more than 60 million people worldwide, and over 80% of them live in resource-poor countries. ¹ Approximately 85% of these people do not receive appropriate treatment ² because of economic, cultural, social and legislative barriers, compounded by little interest on the part of pharmaceutical companies because drug distribution is not lucrative. Left untreated, people with epilepsy face devastating social consequences, including stigma and discrimination, and can even die from seizures. The morbidity and premature mortality associated with epilepsy and the large economic burden the disease imposes on health-care systems can only be mitigated by making effective antiepileptic treatment widely available.